Welcome to our dedicated page for DURECT news (Ticker: DRRX), a resource for investors and traders seeking the latest updates and insights on DURECT stock.
DURECT Corporation (DRRX) is a biopharmaceutical innovator advancing epigenetic treatments and drug delivery systems for complex conditions. This page provides investors and industry professionals with timely updates on clinical trials, regulatory milestones, and strategic developments.
Discover comprehensive coverage of DURECT's pipeline progress, including therapies targeting alcohol-associated hepatitis and pain management. Our curated news collection offers insights into FDA designations, partnership announcements, and research breakthroughs while maintaining strict editorial neutrality.
Key updates include late-stage clinical trial results, intellectual property developments, and analyses of therapeutic mechanisms. Bookmark this resource for streamlined access to verified information about DURECT's epigenetic modulation technologies and commercial strategies.
Bausch Health (NYSE:BHC) has announced the extension of its tender offer deadline to acquire DURECT Corporation (NASDAQ:DRRX). The offer, originally set to expire on September 9, 2025, has been extended to September 10, 2025, at 5:00 p.m. New York City time.
The all-cash transaction values DURECT at $1.75 per share, with an upfront consideration of approximately $63 million at closing. The deal includes potential additional milestone payments of up to $350 million based on net sales achievements of larsucosterol, contingent on meeting targets before the earlier of 10 years after first U.S. commercial sale or December 31, 2045.
DURECT Corporation (Nasdaq: DRRX) has announced its Q2 2025 financial results and provided an update on its proposed acquisition by Bausch Health. Under the merger agreement, Bausch Health will acquire DURECT for $1.75 per share in an all-cash transaction, representing approximately $63 million upfront, plus potential milestone payments of up to $350 million based on net sales achievements.
The transaction is expected to close in Q3 2025, with Bausch Health Americas initiating a tender offer for all outstanding DURECT shares on August 12, 2025. For Q2 2025, DURECT reported total revenues of $447,000 and a net loss of $2.3 million, compared to revenues of $646,000 and a net loss of $3.7 million in Q2 2024. The company's cash position stood at $6.7 million as of June 30, 2025, down from $12.0 million at the end of 2024.
DURECT Corporation (DRRX) reported Q1 2025 financial results, with total revenues of $0.3 million and a net loss of $4.2 million, compared to revenues of $0.5 million and a net loss of $7.6 million in Q1 2024. The company's cash position decreased to $8.4 million as of March 31, 2025, from $12.0 million at the end of 2024.
DURECT is planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH), with topline results expected within two years of initiation. The trial's commencement in 2025 is contingent on securing sufficient funding. The company's Phase 2b AHFIRM trial results were published in NEJM Evidence in January 2025. Additionally, Innocoll Pharmaceuticals transferred all POSIMIR-related data and know-how to DURECT following their licensing agreement termination.
DURECT (DRRX) reported its Q4 and full year 2024 financial results, highlighting key developments in its larsucosterol program for alcohol-associated hepatitis (AH). The company's Phase 2b AHFIRM trial results were published in NEJM Evidence in January 2025, with additional data presented at The Liver Meeting 2024.
Financial highlights include: Q4 2024 revenue of $0.5M with net income of $7.8M, compared to Q4 2023 revenue of $0.9M and net loss of $1.4M. Full year 2024 showed revenue of $2.0M with a net loss of $7.9M, versus 2023 revenue of $2.6M and net loss of $27.6M. Cash position stood at $12.0M as of December 31, 2024.
The company sold its ALZET product line for $17.5M to Lafayette Instrument Co. and used the proceeds to repay its term loan with Oxford Finance DURECT is planning a Phase 3 trial for larsucosterol in severe AH, pending sufficient funding.
DURECT (DRRX), a late-stage biopharmaceutical company focused on epigenetic therapies targeting dysregulated DNA methylation, has scheduled its fourth quarter and full year 2024 financial results announcement for Wednesday, March 26, 2025.
The company will host a conference call and webcast with investors at 4:30 PM Eastern Time / 1:30 PM Pacific Time to discuss the financial results and provide a business update. Investors can access the event through guest dial-in numbers or use the Call me™ link for instant telephone access, which will be activated 15 minutes before the scheduled start time.
DURECT (DRRX) has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference, scheduled for February 11-12, 2025. The company's President and CEO, James E. Brown, will deliver a presentation on Tuesday, February 11, from 2:00-2:30 PM ET on Track 5.
The conference will be held in a virtual format, and interested parties can access the presentation through a webcast link provided. Additionally, DURECT's management team will be available for one-on-one meetings with investors during the conference. Investors seeking to arrange meetings are advised to contact their Oppenheimer representative to schedule appointments.
DURECT (DRRX) has published Phase 2b AHFIRM trial results for larsucosterol in NEJM Evidence. The trial evaluated the drug's safety and efficacy in treating severe alcohol-associated hepatitis (AH) across 307 patients in three arms: placebo, 30mg, and 90mg doses.
The study showed clinically meaningful trends in reducing 90-day mortality, with 41% reduction in the 30mg arm (p=0.068) and 35% in the 90mg arm (p=0.124) compared to placebo. Results were more pronounced in U.S. patients, showing mortality reductions of 57% (p=0.014) and 58% (p=0.008) for 30mg and 90mg doses respectively.
The company plans to initiate a Phase 3 trial in 2025, pending funding. The FDA has indicated that a single Phase 3 trial could support a New Drug Application (NDA). The drug appeared safe and well-tolerated, with treatment emergent adverse events similar to placebo.
DURECT (DRRX) has sold its ALZET® osmotic pumps product line to Lafayette Instrument Co. for $17.5 million. The transaction includes certain assets and liabilities associated with the ALZET line. DURECT used the proceeds to pay off its remaining obligations under the Oxford Finance term loan. The company states this sale strengthens its cash position and extends runway through first half of 2025, allowing focus on developing larsucosterol for alcohol-associated hepatitis (AH) and its planned Phase 3 clinical trial.
DURECT (DRRX) reported Q3 2024 financial results with total revenues of $1.9 million and a net loss of $4.3 million. The company's cash position stood at $10.5 million as of September 30, 2024, down from $29.8 million at year-end 2023. DURECT is preparing for a Phase 3 trial of larsucosterol in severe alcohol-associated hepatitis, pending sufficient funding. The trial will focus on 90-day survival as the primary endpoint, with topline results expected within two years of initiation. Additionally, Innocoll Pharmaceuticals is terminating its POSIMIR® license agreement, effective May 2025.
DURECT (Nasdaq: DRRX), a late-stage biopharmaceutical company focused on epigenetic therapies, announced it will release its third quarter 2024 financial results on Wednesday, November 13, 2024. The company will host a conference call and webcast with investors at 4:30 pm Eastern Time to discuss financial results and provide a corporate update. Participants can join via toll-free number (1-877-407-0784), international number (1-201-689-8560), or through the Call Me™ link and webcast platform.
FAQ
What is the current stock price of DURECT (DRRX)?
What is the market cap of DURECT (DRRX)?
